ReviewMycopathologia2014
Treatment of infections by cryptic Aspergillus species.
Review in Mycopathologia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Coinfection of Pulmonary Hydatid Cyst and Aspergilloma: Case Report and Systematic Review.Mycopathologia · 2016Pooled it
- DecipheringMicrobiology spectrum · 2025Article
- Evaluation of the Activity of Triazoles Against Non-Open forum infectious diseases · 2024Article
- Know the enemy and know yourself: Addressing cryptic fungal pathogens of humans and beyond.PLoS pathogens · 2023Article
- A Practical Workflow for the Identification of Aspergillus, Fusarium, Mucorales by MALDI-TOF MS: Database, Medium, and Incubation Optimization.Journal of clinical microbiology · 2022Article
- Unravelling the Molecular Identification and Antifungal Susceptibility Profiles ofJournal of fungi (Basel, Switzerland) · 2022Article
- Cryptic aspergillosis: a rare entity and a diagnostic challenge.Access microbiology · 2022Article
- Colistin and Isavuconazole Interact Synergistically In Vitro againstMicroorganisms · 2020Article
- Molecular Identification, Antifungal Susceptibility Testing, and Mechanisms of Azole Resistance inAntimicrobial agents and chemotherapy · 2019Article
- Antifungal Susceptibility of the Aspergillus viridinutans Complex: Comparison of TwoAntimicrobial agents and chemotherapy · 2018Article
- Ecology of aspergillosis: insights into the pathogenic potency of Aspergillus fumigatus and some other Aspergillus species.Microbial biotechnology · 2017Review
- Advances against aspergillosis: biology, host response, diagnosis and treatment.Mycopathologia · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The best treatment for patients with invasive aspergillosis caused by cryptic Aspergillus species remains uncertain, mainly due to the limited clinical data that have been published so far. In face of this limitation, patients should be treated with standard first-line therapy for invasive aspergillosis, with therapy being modified according to in vitro susceptibility testing. In this review, we summarize the importance of cryptic Aspergillus species in modern medicine, including their prevalence, methods for detection and response to antifungal drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.